SVP, Head of Biology

Company Summary:

Quotient Therapeutics, Inc. is a privately held, early-stage company developing a novel genomics platform and therapeutics for diseases with a large unmet need.

Quotient Therapeutics, Inc. was founded by Flagship Pioneering, an innovation enterprise that conceives, creates, resources, and grows first-in-category life sciences companies. Flagship Pioneering has created over 100 groundbreaking companies over the past twenty years, all of which are pioneering novel and proprietary biological, industrial, and engineering approaches to solve major needs in human health and sustainability. These companies include Moderna (MRNA), Seres Therapeutics (NASDAQ: MCRB), Sana Biotechnology (SANA), Axcella Health (AXLA), Indigo Agriculture, Generate Biomedicines, and Tessera Therapeutics.

Position Summary:

We are seeking a visionary Head of Biology to develop and advance an industry first pipeline informed by somatic genomics. The position has the unique opportunity to create a vision and implement the strategy that will make a major impact. The Head of Biology will lead cross-validation and prioritization of drug targets, leveraging data-science, functional genomics, biochemistry, mechanistic biology, and disease models. The successful candidate is a confident leader with extensive prior success in drug discovery, preferably in multiple therapeutic areas such as immunology, oncology, metabolic diseases, CNS, etc. Experience with leading and working with computational biology and statistical biology teams to use multi-omics data to inform biology is preferred. The successful candidate will have a track record of accomplishments in drug discovery as well as demonstrated high impact research in academia or industry. S(he) must exhibit excellent leadership, project management, and strong collaboration and communication skills. S(he) should be ready to champion new ideas in a very dynamic and innovative environment.

Responsibilities:

• Direct the execution of multiple early drug discovery programs, including setting scientific direction, development of program timelines, monitoring of key milestones and decision points, and managing scientific team
• Evaluate, triage and cross-validate targets discovered via Quotient’s somatic genomics platform, including functional genomics, mechanistic biology, biochemistry, and disease models
• Oversee the development of in vitro and in vivo pre-clinical models across multiple therapeutic areas
• Work closely with Quotient leadership, defining departmental vision and contributing to cross-company activities and decisions with thoughtful and collaborative engagement
• Recruit, retain and develop a growing team of biologists and pharmacologists
• Maintain close collaboration with data-science, somatic genomics platform, and drug discovery teams
• Perform research and development in collaboration with other functions in projects pertaining to a range of potential indications

Key Qualifications:

• Ph.D. in biology or related discipline with 10+ years of relevant post-Ph.D. experience with an excellent track record of interrogating disease mechanisms and pathways
• Breadth of therapeutic area expertise and exposure to multiple therapeutic modalities, including small molecules and biologics
• Well-versed in target discovery via human genetics
• Experience in high-throughput arrayed and/or pooled reverse genetic screens in human cells
• Track record of selecting targets and contributing to successful drug programs
• Ability to organize and communicate complex data sets in a clear and concise manner to key stakeholders from diverse backgrounds
• Prior experience working with or leading collaborations with external academic, biotechnology, and contract research organizations

Location: Cambridge, MA 

About Flagship

Flagship Pioneering is a bioplatform innovation company that invents and builds platform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, resulting in more than $90 billion in aggregate value. Many of the companies Flagship has founded have addressed humanity’s most urgent challenges: vaccinating billions of people against COVID-19, curing intractable diseases, improving human health, preempting illness, and feeding the world by improving the resiliency and sustainability of agriculture.  Flagship has been recognized twice on FORTUNE’s “Change the World” list, an annual ranking of companies that have made a positive social and environmental impact through activities that are part of their core business strategies, and has been twice named to Fast Company’s annual list of the World’s Most Innovative Companies. Learn more about Flagship at www.flagshippioneering.com.